Chronic sinusitis is a common affliction that affects an\nestimated 37 million Americans each year. The condition is marked by\ninflammation of the sinuses that blocks the nasal passages, causing chronic\ninfections. Symptoms include nasal congestion, sinus pain and pressure, loss of\nsmell and taste, nasal discharge, headache, fatigue and depression. <\/p>\n\n\n\n
Medications may provide temporary relief, but their\neffectiveness over the long term is not very impressive, prompting many\npatients to turn to surgery that involves enlarging the sinus cavities\nresponsible for drainage. While sinus surgery is effective at relieving\nsymptoms, a large number of patients contend with recurrent sinus infections\nwithin a year. At that point they may opt for follow-up surgery, and the\nprocess often repeats itself.<\/p>\n\n\n\n
The Propel steroid-releasing implant is an alternative\ntreatment for patients experiencing chronic sinus infections. It is the first\n(and only) product on the market that targets the inflamed sinus tissues\ndirectly, opening them up for improved drainage and a reduction in symptoms. <\/p>\n\n\n\n
The implant, inserted during an endoscopic sinus procedure,\nresembles a spring and delivers a measured dose of mometasone furoate, an\nanti-inflammatory steroid that gradually dissolves. It is completely absorbed\nby the body four to six weeks after implantation. <\/p>\n\n\n\n
Approved by the FDA in 2013, Propel is safe and effective\nand carries fewer risks of post-surgical scarring or inflammation. Patients\ntypically have a smaller chance of requiring follow-up surgery. <\/p>\n\n\n\n
If you are bothered by chronic sinusitis and are looking for\na long-term solution, schedule an appointment with one of our physicians to\nlearn if Propel is a viable option for you. <\/p>\n\n\n